{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:59:30Z","timestamp":1783771170699,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>During 2023, the leads of the ECNP TWG focused on Clinical Outcomes in Early-Trials in Neurosciences scheduled two brainstorming sessions to allow a deep discussion about challenges facing neurosciences drug development in neuropediatric rare diseases. Sessions were led by Dr Maria T. Acosta from the Undiagnosed Disease Program (UDP) at the National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, EE.UU. The experts discussed about challenges and potential solutions as well as alternative options to design appropriated for clinical outcomes assessment (COA) instruments for this population. An important discussion took place due to extensive expertise of the participants and hands-on experience with clinical trials. Participation from experts from several disciplines was a key factor for appraising and brainstorm innovative solutions in the field. Identification of challenges and propose of innovative solutions were a central core of the discussion. Despite of the increasing number of rare and ultra-rare diseases being identify by the day, and the significant differences in biology, and clinical presentation, it is clear most of them face similar problems when is time to select the appropriated COAs to test potential interventions, and experts have a limited potential to drive efficient solutions. Some of the commonly identified common problems include: small number of patients affected, disease changes over time, developmental aspects impacting the clinical presentation according with age, individual variability in terms of disease severity between patient, variable window for intervention and in some cases, need to expedite treatment as per the disease progression. All these and other features, require an extensive dialogue and continue communication between preclinical researchers, clinicians, patients and family members, pharma and treatment designers and regulatory agencies in each condition, making this process, expensive, time consuming and very difficult to accomplish. A feasible solution, that may be applicable to several conditions, is to develop a \u201cback bone\u201d structure to approach rare diseases, allowing each \u201cdisease team\u201d to tailored assessments and study design, according with the specific features of the condition. We concluded that it is fundamental to establish effective bridges of communication between the different actors implicated in the clinical trial design and execution, sharing experiences, as well as clear understanding of meaningful outcomes not only for researchers, but clinicians, patients and families. Important emphasis is done in the need or careful selection of COAs in each individual condition to be able to obtain more efficient and reliable results in clinical trials in this population. We need to be creative, and there is a need to leave the \u201ccomfort zone\u201d of current methodologies and start piloting new methods at clinical settings. A specific research platform was proposed as a solution in the creation, sharing and validation of new assessment instruments, which would be available to clinicians and researchers attending small patient samples distributed over the world.<\/jats:p>","DOI":"10.1186\/s13023-025-03814-0","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T13:20:48Z","timestamp":1760707248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Methodological challenges in outcomes research for early-trials for implementation of new therapies in neuropediatric rare diseases"],"prefix":"10.1186","volume":"20","author":[{"given":"Maria T.","family":"Acosta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8568-4696","authenticated-orcid":false,"given":"Silvia","family":"Zaragoza Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso","family":"Arango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim I.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Busner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Dorffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s del","family":"Cerro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Carlos","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edna","family":"Gruenblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine M.","family":"H\u00f6lter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Harel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanitha","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pallanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carme","family":"Plasencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kittel-Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella","family":"Tinoco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Vance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manpreet K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 \u00c1ngel","family":"Aibar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella Santuccione","family":"Chadha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estibaliz Arce","family":"Cirauqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"3814_CR1","doi-asserted-by":"publisher","unstructured":"Aartsma-Rus A, Takeda S. A historical perspective on the development of antisense oligonucleotide treatments for Duchenne muscular dystrophy and spinal muscular atrophy. J Neuromuscul Dis. 2025;22143602251317422. https:\/\/doi.org\/10.1177\/22143602251317422.","DOI":"10.1177\/22143602251317422"},{"issue":"Suppl 4","key":"3814_CR2","first-page":"52","volume":"83","author":"MT Acosta","year":"2023","unstructured":"Acosta MT. [Rare diseases and undiagnosed diseases: advances in neurodevelopment]. Medicina. 2023;83(Suppl 4):52\u20136.","journal-title":"Medicina"},{"key":"3814_CR3","doi-asserted-by":"publisher","unstructured":"Bird LM, Ochoa-Lubinoff C, Tan W-H, Heimer G, Melmed RD, Rakhit A, Visootsak J, During MJ, Holcroft C, Burdine RD, Kolevzon A, Thibert RL. The STARS phase 2 study: A randomized controlled trial of Gaboxadol in Angelman syndrome. Neurology. 2021;96(7). https:\/\/doi.org\/10.1212\/WNL.0000000000011409.","DOI":"10.1212\/WNL.0000000000011409"},{"issue":"1\u20133","key":"3814_CR4","first-page":"25","volume":"20","author":"J Busner","year":"2023","unstructured":"Busner J, Pandina G, Day S, Mahableshwarkar A, Kempf L, Sheean M, Dunn J. Patient centricity: design and conduct of clinical trials in orphan diseases: third of three sets of expanded proceedings from the 2020 ISCTM autumn conference on pediatric drug development. Innovations Clin Neurosci. 2023;20(1\u20133):25\u201331.","journal-title":"Innovations Clin Neurosci"},{"issue":"10\u201312","key":"3814_CR5","first-page":"15","volume":"18","author":"J Busner","year":"2021","unstructured":"Busner J, Pandina G, Domingo S, Berger A-K, Acosta MT, Fisseha N, Horrigan J, Ivkovic J, Jacobson W, Revicki D, Villalta-Gil V. Clinician- and Patient-reported endpoints in CNS orphan drug clinical trials: ISCTM position paper on best practices for endpoint selection, validation, training, and standardization. Innovations Clin Neurosci. 2021;18(10\u201312):15\u201322.","journal-title":"Innovations Clin Neurosci"},{"issue":"1","key":"3814_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s11689-025-09591-y","volume":"17","author":"K Campbell","year":"2025","unstructured":"Campbell K, Neul JL, Lieberman DN, Berry-Kravis E, Benke TA, Fu C, Percy A, Suter B, Morris D, Carpenter RL, Marsh ED, Hehn V, J. A randomized, placebo-controlled, cross-over trial of ketamine in Rett syndrome. J Neurodevelopmental Disorders. 2025;17(1):4. https:\/\/doi.org\/10.1186\/s11689-025-09591-y.","journal-title":"J Neurodevelopmental Disorders"},{"key":"3814_CR7","unstructured":"Esbensen AJ, Schworer AK. Contemporary issues in evaluating treatment outcomes in neurodevelopmental disorders. Academic; 2022."},{"key":"3814_CR8","doi-asserted-by":"publisher","unstructured":"Farmer C, Kaat AJ, Berry-Kravis E, Thurm A. (2022). Psychometric perspectives on developmental outcome and endpoint selection in treatment trials for genetic conditions associated with neurodevelopmental disorder. Int Rev Res Dev Disabil, 62:1\u201339. https:\/\/doi.org\/10.1016\/bs.irrdd.2022.05.001","DOI":"10.1016\/bs.irrdd.2022.05.001"},{"issue":"4","key":"3814_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ymgme.2016.01.007","volume":"117","author":"WA Gahl","year":"2016","unstructured":"Gahl WA, Mulvihill JJ, Toro C, Markello TC, Wise AL, Ramoni RB, Adams DR, Tifft CJ. The NIH undiagnosed diseases program and network: applications to modern medicine. Mol Genet Metab. 2016;117(4):393\u2013400. https:\/\/doi.org\/10.1016\/j.ymgme.2016.01.007.","journal-title":"Mol Genet Metab"},{"key":"3814_CR10","doi-asserted-by":"publisher","unstructured":"Glaze DG, Neul JL, Kaufmann WE, Berry-Kravis E, Condon S, Stoms G, Oosterholt S, Della Pasqua O, Glass L, Jones NE, Percy AK, Rett 002 Study Group, Glaze DG, Neul JL, Kaufmann WE, Berry-Kravis E, Condon S, Stoms G, Oosterholt S, Percy A. (2019). Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. Neurology, 92(16). https:\/\/doi.org\/10.1212\/WNL.0000000000007316","DOI":"10.1212\/WNL.0000000000007316"},{"issue":"1\u20133","key":"3814_CR11","first-page":"13","volume":"20","author":"PD Harvey","year":"2023","unstructured":"Harvey PD, Busner J, Pandina G, Taylor HG, Grabb M, Jimenez-Shahed J. Special challenges in pediatric drug development: first of three sets of expanded proceedings from the ISCTM autumn conference on pediatric drug development. Innovations Clin Neurosci. 2023;20(1\u20133):13\u20137.","journal-title":"Innovations Clin Neurosci"},{"issue":"8","key":"3814_CR12","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1089\/cap.2018.0141","volume":"29","author":"E Hesselmark","year":"2019","unstructured":"Hesselmark E, Bejerot S. Patient satisfaction and treatments offered to Swedish patients with suspected pediatric Acute-Onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorders associated with Streptococcal infections. J Child Adolesc Psychopharmacol. 2019;29(8):634\u201341. https:\/\/doi.org\/10.1089\/cap.2018.0141.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"3814_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.5582\/irdr.2018.01085","volume":"7","author":"N Khosla","year":"2018","unstructured":"Khosla N, Valdez R. A compilation of National plans, policies and government actions for rare diseases in 23 countries. Intractable Rare Dis Res. 2018;7(4):213\u201322. https:\/\/doi.org\/10.5582\/irdr.2018.01085.","journal-title":"Intractable Rare Dis Res"},{"key":"3814_CR14","doi-asserted-by":"publisher","unstructured":"Lewis C, Johnston J, Zaragoza Domingo S, Vezina G, D\u2019Souza P, Gahl W, Adams D, Tifft C, Acosta M. (2024). Retrospective assessment of Clinical Global Impression of Severity and Change in GM1 Gangliosidosis: A tool to score natural history data in rare disease cohorts. https:\/\/doi.org\/10.31219\/osf.io\/tscr9","DOI":"10.31219\/osf.io\/tscr9"},{"key":"3814_CR15","doi-asserted-by":"publisher","unstructured":"Lewis CJ, Johnston JM, Zaragoza Domingo S, Vezina G, D\u2019Souza P, Gahl WA, et al. Retrospective assessment of clinical global impression of severity and change in GM1 gangliosidosis: A tool to score natural history data in rare disease cohorts. Orphanet J Rare Dis. 2025;20(1):125. https:\/\/doi.org\/10.1186\/s13023-025-03614-6","DOI":"10.1186\/s13023-025-03614-6"},{"issue":"1\u20133","key":"3814_CR16","first-page":"18","volume":"20","author":"G Pandina","year":"2023","unstructured":"Pandina G, Busner J, Horrigan JP, McSherry C, Bateman-House A, Pani L, Kando J. Implications of pediatric initiatives on CNS drug development for all Ages-2020 and beyond: second of three sets of expanded proceedings from the 2020 ISCTM autumn conference on pediatric drug development. Innovations Clin Neurosci. 2023;20(1\u20133):18\u201324.","journal-title":"Innovations Clin Neurosci"},{"key":"3814_CR17","unstructured":"Pandina G, et al. Ensuring stakeholder feedback in the design and conduct of clinical trials for rare diseases: position paper of the ISCTM orphan disease working group. Innovations in clinical neuroscience. Ahead of Publishing; 2024."},{"key":"3814_CR18","doi-asserted-by":"publisher","unstructured":"Percy AK, Ryther R, Marsh ED, Neul JL, Benke TA, Berry-Kravis EM, Feyma T, Lieberman DN, Ananth AL, Fu C, Buhrfiend C, Barrett A, Doshi D, Darwish M, An D, Bishop KM, Youakim JM. Results from the phase 2\/3 DAFFODIL study of Trofinetide in girls aged 2\u20134 years with Rett syndrome. Med. 2025;100608. https:\/\/doi.org\/10.1016\/j.medj.2025.100608.","DOI":"10.1016\/j.medj.2025.100608"},{"key":"3814_CR19","doi-asserted-by":"publisher","unstructured":"Protic D D., Aishworiya R, Salcedo-Arellano MJ, Tang SJ, Milisavljevic J, Mitrovic F, Hagerman RJ, Budimirovic DB. Fragile X syndrome: from molecular aspect to clinical treatment. Int J Mol Sci. 2022;23(4):1935. https:\/\/doi.org\/10.3390\/ijms23041935.","DOI":"10.3390\/ijms23041935"},{"key":"3814_CR20","unstructured":"Sparrow SS, Balla R, Cicchetti DV. (2016). Vineland-3: Vineland adaptive behavior scales. Manual (Third edition). NCS Pearson."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03814-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03814-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03814-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:43:51Z","timestamp":1781613831000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-03814-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3814"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03814-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"14 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Co-Authors have provided the following list of conflicting interests: Maria T. Acosta, has no conflict of interests. Silvia Zaragoza Domingo, is consultant to pharma industry as Lundbeck A\/S, Sanofi and Jazz Pharmaceuticals and Merck Healthcare. Celso Arango, acts as consultant to a number of pharma companies. Kim I. Bishop, has no conflict of interests. Joan Busner is full-employee at Signant Health may own stock: Signant Health Georg Dorffner, has not conflict of interests. In\u00e9s del Cerro, provides consultancy work to pharma industry as World Clinical Trials. John Carlos Diaz, has not conflict of interests. Edna Gruenblatt, has not conflict of interests. Sabine M. H\u00f6lter, has not conflict of interests. Brian Harel, is employee at Takeda. Vanitha Krishna, has not conflict of interests. Marta Mas, has not conflict of interest. Carmen Moreno, has not conflict of interest. Stefano Pallanti, the following is declared from 2021 to 2023: Recordati, Biohaven Pharmaceuticals, Angelini Pharma, GW Research Limited, Innova Pharma, Swiss National Science Foundation (SNSF), Lundbeck, Otsuka Pharmaceutical, Agence Nationale dela Recherche France, Aboca, Biogen, Menarini, Neopharmed Gentili, Beckley Psytech, Medpace, Acsel Health, R21 Grant NIH Co-PI Clinical Trial NCT03669315 Carme Plasencia, has not conflict of interests. Sarah Kittel-Schneider, Speaker\u2019s honoraria from Medice Arzneimittel Puetter GmbH & CoKG, Takeda and Janssen in the past 3 years. Funding as Co-PI from GB-A Innovationsfond (UplusE and PeriPsych projects). Daniella Tinoco, has not conflict of interests. Monica Vance, owns and actively operate an organization that provides COA-related services, including consulting to the pharma industry. Manpreet K. Singh, USA has received research support from the National Institutes of Health, Patient Centered Outcomes Research Institute, and the Brain and Behavior Research Foundation. She is on a data safety monitoring board for a study funded by the National Institute of Mental Health. She is on the advisory board for Skyland Trail. She receives honoraria from the American Academy of Child and Adolescent Psychiatry, royalties from American Psychiatric Association Publishing, and travel support and\/or honoraria for continuing medical education from Neuroscience Education Institute, Psych Congress, and Medscape. Simona Giorgi, has not conflict of interests. Jos\u00e9 \u00c1ngel Aibar, has not conflict of interests. Antonella Santuccione Chadha, Co-Founder and CEO (pro bono) Women`s Brain Project. Estibaliz Arce, has not conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"521"}}